Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04543331
Other study ID # CRTH258ADE02
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 5, 2020
Est. completion date December 20, 2025

Study information

Verified date May 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care and will take place as per investigator's discretion. This includes e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice will be collected as part of the study.


Description:

BLUE SKY consists of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME". Patients will be enrolled at approximately 55 centers, which will be representatively distributed amongst the 16 German federal states. This will ensure to reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients will be included after decision to start treatment with brolucizumab and consent is given. All patients will be documented either in the AMD or DME-module (Full Analysis Set). For the BIRL module, only naïve nAMD patients enrolled in approximately 7 selected centers will be documented. All these centers are equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice will be collected as part of the study. The study eye will be defined as the first eye treated during the study, the other eye will be considered as fellow eye. If both eyes are treated at baseline, the eye with the worse VA will be chosen as the study eye (if VA is measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient will be up to 24 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 573
Est. completion date December 20, 2025
Est. primary completion date December 20, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: The unit of analysis is patient-eye, i.e. all criteria should be applied to the study eye, unless otherwise specified. Patients will be included in the study if they fulfil the following requisites: 1. Diagnosis of nAMD or visual impairment due to DME 2. Male and Female nAMD and DME patients with =18 years of age at index 3. Decision to treat with brolucizumab at baseline visit 4. Signed written informed consent 5. Patients for whom a therapy with brolucizumab is medically indicated 6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening Exclusion Criteria: 1. Patients that have any contraindication or are not eligible for treatment with brolucizumab as according to the SmPC 2. Patients treated for RVO or CNV other than nAMD 3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date 4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD) 5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date 6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date) 7. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 24 months study participation 8. Patients participating in parallel in an interventional clinical trial 9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug 10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline 11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline 12. Pregnancy and breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
brolucizumab
There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Locations

Country Name City State
Germany Novartis Investigative Site Aschersleben
Germany Novartis Investigative Site Bayreuth
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Breisach am Rhein
Germany Novartis Investigative Site Chemnitz
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Esslingen
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Glauchau
Germany Novartis Investigative Site Gottingen
Germany Novartis Investigative Site Halle
Germany Novartis Investigative Site Homburg
Germany Novartis Investigative Site Hösbach
Germany Novartis Investigative Site Jena
Germany Novartis Investigative Site Kiel
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Magdeburg
Germany Novartis Investigative Site Marienberg
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenster
Germany Novartis Investigative Site Neubrandenburg
Germany Novartis Investigative Site Neuburg
Germany Novartis Investigative Site Osnabrück
Germany Novartis Investigative Site Rostock
Germany Novartis Investigative Site Saarbruecken
Germany Novartis Investigative Site Schneeberg Sachsen
Germany Novartis Investigative Site Schoenebeck
Germany Novartis Investigative Site Stralsund
Germany Novartis Investigative Site Sulzbach
Germany Novartis Investigative Site Torgau
Germany Novartis Investigative Site Trier RP
Germany Novartis Investigative Site Waren
Germany Novartis Investigative Site Wuerzburg
Germany Novartis Investigative Site Wuerzburg Bayern

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) This outcome measure is part of the BLUE SKY AMD module. This primary study objective will be addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). Month 12
Primary Mean change in visual actuity (VA) under clinic specific routine treatment schemes This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.
Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.
Baseline, month 12
Primary Morphological CNV-Changes under clinic specific routine treatment schemes This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.
Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.
Baseline, month 12
Primary Percent of patients maintained on q12w dosing after loading through Week 52 This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering treatment naïve patient eyes included in the study. After loading, month 12
Primary Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months) This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. Baseline, month 12
Secondary Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Baseline
Secondary Evaluate anatomical parameters during treatment with brolucizumab nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. Up to month 24
Secondary Evaluate VA change from baseline during treatment with brolucizumab nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. Baseline, month 24
Secondary Estimate number of anti-VEGF injections, visits and injection intervals nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Estimate percentage of switchers during first 6 months and characterize switchers nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Baseline, month 6
Secondary Estimate discontinuation rate and time to discontinuation nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 1-12 and 13-24
Secondary Assess retreatment criteria nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Estimate the number of OCT nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 1-12 and 13-24
Secondary Assess the safety of brolucizumab nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Evaluate anatomical effectiveness naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Evaluate treatment intervals naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Describe implementation of treatment schemes into clinical practice naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Evaluate morphological changes under brolucizumab treatment using multimodal imaging naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch) DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 12
Secondary Evaluate anatomical parameters during treatment with brolucizumab DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 1-12 and 13-24
Secondary Characterize VA change from baseline during treatment with brolucizumab DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 1-12 and 13-24
Secondary Estimate discontinuation rate during first year of brolucizumab treatment DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Baseline, month 12
Secondary Estimate time to discontinuation (persistence) DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Up to month 24
Secondary Estimate the treatment burden DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan Month 1-12 and 13-24
Secondary Estimate the number of OCT and the number of visits with/without OCT DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. Month 1-12 and 13-24
Secondary Assess safety of brolucizumab DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. Up to month 24
See also
  Status Clinical Trial Phase
Completed NCT01702441 - Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Completed NCT02424019 - Phase 4 IOP Signals Associated With ILUVIEN® Phase 4
Completed NCT02633852 - Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Phase 4
Completed NCT04857996 - Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) Phase 2
Recruiting NCT05919693 - A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Phase 1/Phase 2
Completed NCT04739306 - Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema Phase 3
Recruiting NCT06116916 - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema Phase 2
Completed NCT02050828 - The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A
Terminated NCT02080091 - Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies N/A
Terminated NCT04697758 - Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Terminated NCT00936520 - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Phase 1
Not yet recruiting NCT06398080 - An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Active, not recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3